Back to Market返回行情

KLTO Klotho Neurosciences, Inc.

USHealthcare
$0.3810-7.10%ClosedMarket Cap: $20.1M

As of 2026-03-16 15:59

Why KLTO matters now

Klotho Neurosciences, Inc. (KLTO) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.38 with -7.10% on the session and $20.1M in market capitalization; recent performance reads 1-month -7.10% and YTD +31.83%.

The latest financial table shown here is Q3 2025, with revenue of $0.00, net income of $-2.9M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.9%.

The latest indexable market news headline is "Klotho Neurosciences (NASDAQ:KLTO) and Xenetic Biosciences (NASDAQ:XBIO) Head to Head Contrast" from Defense World.

Additional event context on this page matters because recent insider activity includes SINKULE JOSEPH filing A-Award. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

2.22

P/S

0.00

EV/EBITDA

-1.94

DCF Value

$-0.01

FCF Yield

-27.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-137.6%

ROA

-110.0%

ROIC

-75.1%

Financials

PeriodRevenueNet IncomeEPS
Q3 2025$0.00$-2.9M$-0.05
Q2 2025$0.00$-4.1M$-0.12
Q1 2025$0.00$-2.2M$-0.08
Q4 2024$0.00$-2.1M$-0.08

Trading Activity

Insider Trades

SINKULE JOSEPHdirector, officer: Chief Executive Officer
Sell2026-03-06
McGarity Jondirector
Sell2026-03-06
Hirschman Shalomdirector
Sell2026-03-06
ZENTMAN SAMUEL Mdirector
Sell2026-03-06
El-Dada Riad Husseindirector
Sell2026-03-06

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

2.23

Klotho Neurosciences, Inc. operates as a biopharmaceutical enterprise focused on devising medical treatments for various conditions, including cancer, cardiovascular ailments, and neurodegenerative disorders. Their leading gene therapy assets encompass AMI-101, which is designed for the management or prevention of Alzheimer's disease, and AMI-202, aimed at treating or averting amyotrophic lateral sclerosis. Formerly known as Anew Medical, Inc., the company underwent a name change to Klotho Neurosciences, Inc. in September 2024. The firm's main office is situated in Omaha, Nebraska.